All rifamycin articles
-
NewsCDI breakthroughs lead to new drug development deal for deadly NTM bacteria
Scientists have developed new compounds against non-tuberculous mycobacteria which are now the subject of a new collaboration and license agreement with the Switzerland-based and publicly listed BioVersys AG.